The bottleneck in drug development is not data — it is memory. Brioche reads the field's own evidence and writes it back, in time, for the team making the next decision.
Regulatory pathway reads, competitive landscape analysis, deal diligence, continuous coverage of a therapeutic area. Decision intelligence — written by analysts and signed by a named reviewer.
Patient or program context in. Optimized therapeutic out. Modality-agnostic and indication-agnostic by construction — small molecules, biologics, peptides, ASOs, nucleic-acid therapies; oncology, rare disease, autoimmune, metabolic, neurology. Same engine, different intent.
Twenty-eight regulatory and clinical sources. Continuously refreshed. Every claim cited to a primary source with a retrieval timestamp. Every brief reviewed and signed by a named human before it leaves the practice.
ALCOA+ data integrity, version control consistent with 21 CFR Part 11, a software lifecycle aligned to IEC 62304 Class B conventions, named-reviewer signature, and a seven-year audit-trail retention bundled with every deliverable.
Read the posture →A biotech CEO, an R&D director, a BD lead, a regulatory affairs head — each comes to Brioche with a different question, and leaves with a written brief their team can act on this week.
A small number of active engagements with biotech and pharma teams against live regulatory and commercial questions. Real engagement, real deliverable, named-reviewer signature.
Apply to the pilot →